year 17, Issue 3 (May - June 2023)                   Iran J Med Microbiol 2023, 17(3): 324-328 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Molaee H, Davoudi-Monfared E, Allahyari F, Hosseini Nejad J. Evaluation of COVID-19 Incidence in Psoriatic Patients Receiving Adalimumab. Iran J Med Microbiol 2023; 17 (3) :324-328
1- Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
2- Health Management Research Center, Department of Community Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran ,
3- Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
Abstract:   (578 Views)

Background and Aim: Adalimumab is a highly human monoclonal antibody that binds to tumor necrosis factor, a key proinflammatory cytokine pathogenic in psoriasis. It is considered as an influential factor in controlling moderate to severe psoriasis. This study aimed to evaluate the impact of Adalimumab on COVID-19 incidence in patients with psoriasis.
Materials and Methods: This cross-sectional study was performed at Baqiyatallah Hospital in 2021. Eighty patients with psoriasis who referred to Baqiyatallah Hospital were included in the study. Patients were divided into two groups, one group was treated with Adalimumab, and the other group received the control treatment. The incidence of the disease was assessed by the history of COVID-19 signs and symptoms, positive RT‐ PCR testing and graphing, and physician diagnosis.
Results: The mean age of patients was 39.5 (±7.9 S.D.). 36(45%) patients were infected with COVID-19, and 44 (55%) patients were not infected, and there was no significant difference between the two groups in the infection with COVID-19 (P value = 0.36). There was a significant relationship between infection with COVID-19 and the severity of psoriasis (P value=0.01).  Although, in the severe psoriasis group, which was significantly more affected by COVID-19, there was no statistically significant relationship between Adalimumab consumption and COVID-19 affection (P value = 0.19).
Conclusion: PPsoriasis patients treated with Adalimumab are not more prone to COVID-19 infection. However, patients with severe psoriasis are more likely to develop COVID-19; this matter is not related to the use of Adalimumab, and it is not necessary to discontinue or change Adalimumab.

Full-Text [PDF 415 kb]   (158 Downloads) |   |   Full-Text (HTML)  (88 Views)  
Type of Study: Original Research Article | Subject: Medical Virology
Received: 2022/09/7 | Accepted: 2023/01/29 | ePublished: 2023/06/26

1. Subbarao K, Mahanty S. Respiratory Virus Infections: Understanding COVID-19. Immunity. 2020;52(6):905-9. [DOI:10.1016/j.immuni.2020.05.004] [PMID] [PMCID]
2. Lal SK. Molecular biology of the SARS-coronavirus: Springer; 2010. [DOI:10.1007/978-3-642-03683-5]
3. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015;12(1):1-21. [DOI:10.1186/s12985-015-0439-5] [PMID] [PMCID]
4. Mohanty SK, Satapathy A, Naidu MM, Mukhopadhyay S, Sharma S, Barton LM, et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology perspective on current knowledge. Diagn Pathol. 2020;15:1-17. [DOI:10.1186/s13000-020-01017-8] [PMID] [PMCID]
5. Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552-61. [DOI:10.1128/JVI.01890-13] [PMID] [PMCID]
6. Sallenave J-M, Guillot L. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets? Front Immunol. 2020;11:1229. [DOI:10.3389/fimmu.2020.01229] [PMID] [PMCID]
7. Karimian M, Jamshidbeigi A, Badfar G, Azami M. Laboratory findings in coronavirus disease 2019 (COVID-19) patients: a comprehensive systematic review and meta-analysis. medRxiv. 2020:2020-06. [DOI:10.1101/2020.06.07.20124602]
8. Samprathi M, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. Front Pediatr. 2021;8:607647. [DOI:10.3389/fped.2020.607647] [PMID] [PMCID]
9. Hong L-Z, Shou Z-X, Zheng D-M, Jin X. The most important biomarker associated with coagulation and inflammation among COVID-19 patients. Mol Cell Biochem. 2021;476(7):2877-85. [DOI:10.1007/s11010-021-04122-4] [PMID] [PMCID]
10. Eljilany I, Elzouki A-N. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. Vasc Health Risk Manag. 2020(16):455-62. [DOI:10.2147/VHRM.S280962] [PMID] [PMCID]
11. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26(3):107-8. [DOI:10.1136/bmjebm-2020-111536] [PMID] [PMCID]
12. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4-5):490-5. [DOI:10.1016/j.autrev.2014.01.008] [PMID]
13. Traub M, Marshall K. Psoriasis--pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev. 2007;12(4):319-30.
14. Liu Y, Yang G, Zhang J, Xing K, Dai L, Cheng L, et al. Anti-TNF-α monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. Int Immunopharmacol. 2015;28(1):731-43. [DOI:10.1016/j.intimp.2015.07.036] [PMID]
15. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-15. [DOI:10.1016/j.jaad.2007.09.010] [PMID]
16. Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60-71. [DOI:10.1016/j.jaci.2020.10.007] [PMID] [PMCID]
17. Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. J Am Acad Dermatol. 2021;84(2):513-7. [DOI:10.1016/j.jaad.2020.10.046] [PMID] [PMCID]
18. Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J Dermatolog Treat. 2022;33(2):699-703. [DOI:10.1080/09546634.2020.1789051] [PMID]
19. Piaserico S, Gisondi P, Cazzaniga S, Naldi L. Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. Am J Clin Dermatol. 2020;21(5):749-51. [DOI:10.1007/s40257-020-00552-w] [PMID] [PMCID]
20. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(suppl 2):ii65-ii8. [DOI:10.1136/ard.2004.031237] [PMID] [PMCID]
21. Yokota S, Miyamae T, Kuroiwa Y, Nishioka K. Novel Coronavirus Disease 2019 (COVID-19) and Cytokine Storms for More Effective Treatments from an Inflammatory Pathophysiology. J Clin Med. 2021;10(4):801. [DOI:10.3390/jcm10040801] [PMID] [PMCID]
22. Que Y, Hu C, Wan K, Hu P, Wang R, Luo J, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol. 2022;41(2):217-30. [DOI:10.1080/08830185.2021.1884248] [PMID] [PMCID]
23. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382-5. [DOI:10.1080/22221751.2020.1729069] [PMID] [PMCID]
24. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nat Commun. 2020;11(1):2251. [DOI:10.1038/s41467-020-16256-y] [PMID] [PMCID]
25. Atzeni F, Masala IF, Rodríguez-Carrio J, Ríos-Garcés R, Gerratana E, La Corte L, et al. The Rheumatology Drugs for COVID-19 Management: Which and When? J Clin Med. 2021;10(4):783. [DOI:10.3390/jcm10040783] [PMID] [PMCID]
26. Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M. Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment. Cells. 2021;10(2):323. [DOI:10.3390/cells10020323] [PMID] [PMCID]
27. Tursi A, Angarano G, Monno L, Saracino A, Signorile F, Ricciardi A, et al. COVID-19 infection in Crohn's disease under treatment with adalimumab. Gut. 2020;69(7):1364-5. [DOI:10.1136/gutjnl-2020-321240] [PMID]
28. Kara Polat A, Oguz Topal I, Karadag AS, Aksoy H, Koku Aksu AE, Ozkur E, et al. The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatol Ther. 2021;34(1):e14691. [DOI:10.1111/dth.14691] [PMCID]
29. Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G. The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. Vaccines. 2020;8(4):728. [DOI:10.3390/vaccines8040728] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc